Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Centessa Pharmaceuticals plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CNTA
Nasdaq
2836
www.centessa.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Centessa Pharmaceuticals plc
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Jan 28th, 2025 1:00 pm
Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?
- Jan 13th, 2025 2:51 pm
Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?
- Jan 9th, 2025 10:14 pm
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
- Jan 8th, 2025 12:05 pm
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate
- Jan 1st, 2025 10:17 am
Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?
- Dec 20th, 2024 3:31 pm
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
- Nov 13th, 2024 11:15 am
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
- Nov 12th, 2024 12:00 pm
Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech
- Oct 12th, 2024 2:18 pm
Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments
- Oct 9th, 2024 12:04 pm
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Sep 26th, 2024 10:00 am
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
- Sep 13th, 2024 2:34 am
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
- Sep 11th, 2024 8:04 pm
Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity
- Sep 10th, 2024 8:34 pm
Top Midday Gainers
- Sep 10th, 2024 6:09 pm
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
- Sep 10th, 2024 4:19 pm
Investors are waking up to Centessa’s sleepiness drug
- Sep 10th, 2024 12:15 pm
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
- Sep 10th, 2024 11:00 am
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Aug 27th, 2024 12:00 pm
Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...
- Aug 24th, 2024 5:18 am
Scroll